Health and Fitness Health and Fitness
Wed, November 23, 2011
[ Wed, Nov 23rd 2011 ] - Market Wire
00 a.m. ET
[ Wed, Nov 23rd 2011 ] - Market Wire
00 a.m. EST
Tue, November 22, 2011
[ Tue, Nov 22nd 2011 ] - Market Wire
BD Board Increases Dividend
Mon, November 21, 2011
Sun, November 20, 2011
Fri, November 18, 2011
Thu, November 17, 2011
Wed, November 16, 2011
Tue, November 15, 2011
Mon, November 14, 2011
Sun, November 13, 2011
Sat, November 12, 2011
Fri, November 11, 2011

University of Florida Research Foundation and Diamyd Medical settle lawsuit


//health-fitness.news-articles.net/content/2011/ .. oundation-and-diamyd-medical-settle-lawsuit.html
Published in Health and Fitness on Thursday, November 17th 2011 at 1:01 GMT by Market Wire   Print publication without navigation


STOCKHOLM--([ ])--Regulatory News:

University of Florida Research Foundation, Incorporated (aUFRFa), and Diamyd Medical AB (STO:DIAMB)(Pink Sheets:DMYDY) today jointly announced that they have settled the breach of contract litigation that UFRF filed in the United States Federal District Court in Florida against Diamyd Medical in January 2011.

The dispute related to an exclusive license agreement between UFRF and Diamyd Medical, and to a sublicense of the rights under the exclusive license agreement between Diamyd Medical and Ortho-McNeil-Janssen Pharmaceuticals, Inc., which sublicense involved rights to the GAD65-based drug candidate Diamyd.

UFRF and Diamyd Medical have amicably settled their dispute for an undisclosed settlement amount. The settlement amount is in line with what Diamyd Medical has reserved in its accounts as per August 31, 2011 regarding litigation claims. UFRF and Diamyd Medical declined further comment on the matter, citing the confidentiality of their settlement.

About Diamyd Medical

Diamyd Medical is a Swedish biotech company focusing on the development of pharmaceuticals for the treatment of pain, neuropathy and autoimmune diabetes. The portfolio of development projects for the treatment of chronic pain and neuropathy uses the Companyas patented NTDDS (Nerve Targeting Drug Delivery System) platform to administer therapeutic agents directly to the nervous system. The development project within the area of diabetes consists of the protein GAD65 for the treatment and prevention of autoimmune diabetes.

Diamyd Medical has offices in Sweden and in the US. Shares are listed on Nasdaq OMX in Stockholm (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is available on the Companyas website: [ www.diamyd.com ].

This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements.

Diamyd Medical AB (publ.)
Karlavgen 108, SE-115 26 Stockholm, Sweden. Tel: +46 (0)8 6610026, Fax: +46 (0)8 661 63 68
E-mail: [ info@diamyd.com ]. VAT no: SE556530-142001

This information was brought to you by Cision [ http://www.cisionwire.com ]


Publication Contributing Sources